Latest News

Phase 2 CRDF-004 results revealed that the addition of onvansertib to chemotherapy/bevacizumab was well-tolerated, with no unexpected toxicities observed.
Onvansertib Exhibits Encouraging Responses in RAS-Mutant Metastatic CRC

July 30th 2025

Phase 2 CRDF-004 results revealed that the addition of onvansertib to chemotherapy/bevacizumab was well-tolerated, with no unexpected toxicities observed.

Results from the phase 3 MATTERHORN trial support the FDA’s designations for durvalumab in gastric/gastroesophageal junction cancers.
Durvalumab Earns Priority Review, Breakthrough Status in Gastric Cancer

July 28th 2025

Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.
EC Approves Cabozantinib Monotherapy in Previously Treated pNET/epNET

July 25th 2025

Radiotherapy Plus Sintilimab and Chemo Improves pCR in Rectal Cancer
Radiotherapy Plus Sintilimab and Chemo Improves pCR in Rectal Cancer

July 20th 2025

Perioperative Chemo Improves Survival, Control in Esophageal Cancer
Perioperative Chemo Improves Survival, Control in Esophageal Cancer

July 19th 2025

Latest CME Events & Activities

More News